Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 16/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24999532 | 0.85 | SLC6A4 (0.42) | PLA2G7PPARG | |
| SCHEMBL24998717 | 0.83 | AR (0.46) | PLA2G7PPARGSCN9A | |
| SCHEMBL24998721 | 0.82 | PPARG (0.51) | PPARGSCN9A | |
| SCHEMBL25737338 | 0.82 | PLA2G7 (0.56) | PLA2G7 | |
| SCHEMBL16319689 | 0.79 | AR (0.48) | PLA2G7SCN9A | |
| SCHEMBL17884205 | 0.79 | PLA2G7 (0.53) | PLA2G7PPARGSCN9A | |
| SCHEMBL9901518 | 0.79 | PLA2G7 (0.53) | PLA2G7 | |
| SCHEMBL9108605 | 0.79 | PLA2G7 (0.45) | PLA2G7SCN9A | |
| SCHEMBL9103130 | 0.79 | PLA2G7 (0.47) | PLA2G7SCN9A | |
| SCHEMBL29851798 | 0.79 | PLA2G7 (0.47) | PLA2G7SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | PLA2G7 18/4885PPARG 558/4885SCN9A 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.